Pamela B. Greene

Member vCard


  • Boston University School of Law (JD, cum laude, 1991)
  • McGill University (BCOMM, Finance / International Business, 1986)

Bar Admissions

  • Massachusetts

Pam provides executive compensation and securities law advice in public offerings and merger and acquisition transactions. She regularly counsels Mintz Levin’s public company clients with respect to securities compliance under both the Securities Act of 1933 and the Securities Exchange Act of 1934; executive compensation-related issues; and corporate governance matters, including compliance with stock exchange requirements, the Sarbanes-Oxley Act of 2002, and the Dodd-Frank Act of 2010. In addition, she represents both private corporations and investors in financing transactions, executive compensation matters, and general corporate law matters. 

Pam works with individuals, boards, and compensation committees to develop and design appropriate equity and executive compensation programs, and to resolve legal issues confronting employers when implementing and revising such programs.

Before joining Mintz Levin, Pam was an associate in the business practice group of another premier Boston-based law firm. She has advised venture capital fund clients and participated in the organization of venture capital funds. Pam has also handled corporate and securities law matters for a range of businesses, including entrepreneurial companies and private equity investors. She represented both corporations and investors in private placements, public offerings, mergers and acquisitions, and general corporate law matters.

Before attending law school, Pam worked as a corporate service representative for the Boston Trade Bank from its inception as a start-up venture. In that capacity, she handled cash management products and worked with clients to maximize short-term corporate funds.

Representative Matters

Mergers & Acquisitions

  • Myriad Genetics in its acquisition of Assurex Health
  • EnerNOC, Inc. in its acquisition of Pulse Energy Inc.
  • Ember Corporation in its sale to Silicon Laboratories, Inc. 
  • Vringo, Inc. in its merger with Innovate/Protect, Inc. 
  • Caliper Life Sciences, Inc. in its sale to PerkinElmer, Inc. 
  • Microfluidics International Corporation in its sale to IDEX Corporation 
  • Arbinet Corporation in its sale to Primus Telecommunications Group, Inc. 
  • Biocius Life Sciences, Inc. in its sale to Agilent Technologies 
  • AMICAS, Inc. in its sale to Merge Healthcare 
  • Myriad Genetics, Inc. in its spin-off transaction, which resulted in a new public company, Myriad Pharmaceuticals, Inc. 
  • Vertex Pharmaceuticals Incorporated in its acquisition of ViroChem Pharma, Inc. 
  • QIAGEN NV in its acquisition of Digene, Inc. 
  • iBasis, Inc. in its sale to Royal KPN, NV
  • Served as executive compensation counsel to management of BioFire Diagnostics in its sale to BioMérieux

Public Offerings

  • Pieris Pharmaceuticals, Inc. in the filing of its initial public offering 
  • Aspen Aerogels, Inc. in the filing of its initial public offering
  • Intra-Cellular Therapies, Inc. in its reverse merger and initial public offering
  • Intercept Pharmaceuticals, Inc. in the filing of its initial public offering 

Venture Capital Financings

  • Lantos Technologies, Inc. in its venture capital financings
  • ADVANDX Pharmaceuticals, Inc. in its venture capital financings 

Professional & Community Involvement

  • Member, National Association of Stock Plan Professionals
  • Mentor, WOMEN Unlimited, Inc.

Recognitions & Awards

  • Paul J. Liacos Distinguished Scholar 
  • Edward F. Hennessey Scholar 
  • G. Joseph Tauro Scholar

Create PDF


  • Publications
    • Alerts & Advisories
    • Industry Reports & Newsletters
    • Published Articles
  • Speaking Engagements
  • Newsroom
    • Press Releases
    • In The News